Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Panos Kottaridis, Janet North, Ismail Bakhsh, Edward Samuel, Stephen Mackinnon, Mark W Lowdell, PhD, FRCPath

Blood (2008) 112 (11): 2901.

https://doi.org/10.1182/blood.V112.11.2901.2901

Published: 2008

Journal Articles

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

Mark W. Lowdell, PhD, Ismail Bakhsh, MSc, Janet North, MSc, Chloe Marden, PhD, Elena Addison, MSc, Stephen Mackinnon, MD

Blood (2006) 108 (11): 3707.

https://doi.org/10.1182/blood.V108.11.3707.3707

Published: 2006

Journal Articles

CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets.

Chloe M. Marden, PhD, Janet North, MSc, Robert Anderson, PhD, Ismail A. Bakhsh, MSc, Elena Addison, MSc, Hannah Pittman, BSc, Stephen Mackinnon, MD FRCP FRCPath, Mark W. Lowdell, PhD MRCPath

Blood (2005) 106 (11): 3322.

https://doi.org/10.1182/blood.V106.11.3322.3322

Published: 2005

Journal Articles

Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils

Abdelilah Soussi Gounni, Bernard Gregory, Esra Nutku, Fadi Aris, Koussih Latifa, Eleanor Minshall, Janet North, Jan Tavernier, Roy Levit, Nick Nicolaides, Douglas Robinson, Qutayba Hamid

Blood (2000) 96 (6): 2163–2171.

https://doi.org/10.1182/blood.V96.6.2163

Published: 2000

Journal Articles

Interleukin 5 regulates the isoform expression of its own receptor α-subunit

Jan Tavernier, José Van der Heyden, Annick Verhee, Guy Brusselle, Xaveer Van Ostade, Joël Vandekerckhove, Janet North, Sara M. Rankin, A. Barry Kay, Douglas S. Robinson

Blood (2000) 95 (5): 1600–1607.

https://doi.org/10.1182/blood.V95.5.1600.005k22_1600_1607

Published: 2000

NARROW

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets.

Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils

Interleukin 5 regulates the isoform expression of its own receptor α-subunit

Email alerts

ASH Publications

American Society of Hematology

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets.

Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils

Interleukin 5 regulates the isoform expression of its own receptor α-subunit

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only